The effect of low molecular weight heparin (enoxaparin) on enhanced coagulation induced by crystalloid haemodilutionLLEWELLYN, R. L; JAMES, M. F. M.Anaesthesia. 2010, Vol 65, Num 10, pp 1013-1016, issn 0003-2409, 4 p.Article

Enoxaparin and Antifactor Xa Levels in Acute Burn PatientsLIN, Hsin; FARAKLAS, Iris; COCHRAN, Amalia et al.Journal of burn care & research. 2011, Vol 32, Num 1, pp 1-5, issn 1559-047X, 5 p.Article

Use of thromboelastography to demonstrate persistent anticoagulation after stopping enoxaparinSIMONS, R; MALLETT, S. V.Anaesthesia. 2007, Vol 62, Num 11, pp 1175-1178, issn 0003-2409, 4 p.Article

Enoxaparin as bridging anticoagulant treatment in cardiac surgeryRLIVAS-GANDARA, N; FERREIRA-GONZALEZ, I; TORNOS, P et al.Heart (London 1996). 2008, Vol 94, Num 2, pp 205-210, issn 1355-6037, 6 p.Article

Generic low-molecular-weight heparins: Some practical considerationsFAREED, Jawed; LEONG, Wendy L; HOPPENSTEADT, Debra A et al.Seminars in thrombosis and hemostasis. 2004, Vol 30, Num 6, pp 703-713, issn 0094-6176, 11 p.Conference Paper

Patch-test positivity in cutaneous reactions to enoxaparinENRIQUE, E; ALIJOTAS, J; CISTERO, A et al.Contact dermatitis. 2000, Vol 42, Num 1, issn 0105-1873, p. 43Article

Enoxaparin Anticoagulation Monitoring in the Catheterization Laboratory Using a New Bedside TestSILVAIN, Johanne; BEYGUI, Farzin; COLLET, Jean-Philippe et al.Journal of the American College of Cardiology. 2010, Vol 55, Num 7, pp 617-625, issn 0735-1097, 9 p.Article

Edoxaban administration following enoxaparin: A pharmacodynamic, pharmacokinetic, and tolerability assessment in human subjectsZAHIR, Hamim; MATSUSHIMA, Nobuko; HALIM, Abdel-Baset et al.Thrombosis and haemostasis. 2012, Vol 108, Num 1, pp 166-175, issn 0340-6245, 10 p.Article

Timing of postpartum enoxaparin administration and severe postpartum hemorrhageFREEDMAN, Rachel A; BAUER, Kenneth A; NEUBERG, Donna S et al.Blood coagulation & fibrinolysis. 2008, Vol 19, Num 1, pp 55-59, issn 0957-5235, 5 p.Article

Individualized Compared With Conventional Dosing of EnoxaparinBARRAS, M. A; DUFFULL, S. B; ATHERTON, J. J et al.Clinical pharmacology and therapeutics. 2008, Vol 83, Num 6, pp 882-888, issn 0009-9236, 7 p.Article

Ultra-low-molecular-weight heparins: Precise structural features impacting specific anticoagulant activitiesLIMA, Marcelo A; VISKOV, Christian; HERMAN, Frederic et al.Thrombosis and haemostasis. 2013, Vol 109, Num 3, pp 471-478, issn 0340-6245, 8 p.Article

Structure and haemostatic effects of generic versions of enoxaparin available for clinical use in Brazil: Similarity to the original drugGLAUSER, Bianca F; VAIRO, Bruno C; OLIVEIRA, Stephan-Nicollas M. C. G et al.Thrombosis and haemostasis. 2012, Vol 107, Num 2, pp 302-314, issn 0340-6245, 13 p.Article

The utility of thromboelastography in monitoring low molecular weight heparin therapy in the coronary care unitWHITE, Hayden; SOSNOWSKI, Kellie; BIRD, Robert et al.Blood coagulation & fibrinolysis. 2012, Vol 23, Num 4, pp 304-310, issn 0957-5235, 7 p.Article

Enoxaparin Outcomes in Patients With Moderate Renal ImpairmentDECAROLIS, Douglas D; THORSON, Joey G; CLAIRMONT, Megan A et al.Archives of internal medicine (1960). 2012, Vol 172, Num 22, pp 1713-1718, issn 0003-9926, 6 p.Article

High Incidence of Complications From Enoxaparin Treatment After ArthroplastyNEVIASER, Andrew S; CHANG, Charles; LYMAN, Stephen et al.Clinical orthopaedics and related research. 2010, Vol 468, Num 1, pp 115-119, issn 0009-921X, 5 p.Conference Paper

Apixaban or Enoxaparin for Thromboprophylaxis after Knee ReplacementRUD LASSEN, Michael; RASKOB, Gary E; GALLUS, Alexander et al.The New England journal of medicine. 2009, Vol 361, Num 6, pp 594-604, issn 0028-4793, 11 p.Article

Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarctionANTMAN, Elliott M; MORROW, David A; WHITE, Harvey D et al.The New England journal of medicine. 2006, Vol 354, Num 14, pp 1477-1488, issn 0028-4793, 12 p.Article

Positively charged polyethylenimines enhance nasal absorption of the negatively charged drug, low molecular weight heparinTIANZHI YANG; HUSSAIN, Alamdar; SHUHUA BAI et al.Journal of controlled release. 2006, Vol 115, Num 3, pp 289-297, issn 0168-3659, 9 p.Article

Enoxaparin : A review of its use as thromboprophylaxis in acutely ill, nonsurgical patientsSIDDIQUI, M. Asif A; WAGSTAFF, Antona J.Drugs (Basel). 2005, Vol 65, Num 7, pp 1025-1036, issn 0012-6667, 12 p.Article

Efficacy and safety of a new streptokinase regimen with enoxaparin in acute myocardial infarctionTATU-CHITOIU, Gabriel; TEODORESCU, Cristina; DAN, Monica et al.Journal of thrombosis and thrombolysis. 2003, Vol 15, Num 3, pp 171-179, issn 0929-5305, 9 p.Article

Comparison of the use of enoxaparin versus unfractionated heparin in patients undergoing lower extremity revascularizationPARAMO, Juan Carlos; SENDZISCHEW, Harry; SIVINA, Manuel et al.Vascular and endovascular surgery. 2002, Vol 36, Num 3, pp 199-205, issn 1538-5744Article

Novel design of peptides to reverse the anticoagulant activities of heparin and other glycosaminoglycansSCHICK, Barbara P; GRADOWSKI, Joel F; SAN ANTONIO, James D et al.Thrombosis and haemostasis. 2001, Vol 85, Num 3, pp 482-487, issn 0340-6245Article

Severe postoperative haemorrhage and airway obstruction following high-dose enoxaparinWILSON, Michael D; HARRISON, Kenneth.Medical journal of Australia. 2001, Vol 175, Num 3, pp 167-168, issn 0025-729XArticle

Use of enoxaparin in a pregnant woman with a mechanical heart valve prosthesisELLISON, J; THOMSON, A. J; WALKER, I. D et al.BJOG (Oxford. Print). 2001, Vol 108, Num 7, pp 757-759, issn 1470-0328Article

Heparin-induced thrombocytopenia presenting after the cessation of low molecular weight heparin prophylaxis with enoxaparinBARRATT, S. M; RUFF, S. J; EDWARDS, R. C et al.Medical journal of Australia. 2000, Vol 172, Num 9, issn 0025-729X, p. 449Article